- Previous Close
34,600.00 - Open
34,000.00 - Bid 34,150.00 x --
- Ask 34,200.00 x --
- Day's Range
32,950.00 - 34,950.00 - 52 Week Range
21,200.00 - 47,250.00 - Volume
605,572 - Avg. Volume
1,266,525 - Market Cap (intraday)
1.636T - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50,500.00
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
www.ablbio.comRecent News: 298380.KQ
View MorePerformance Overview: 298380.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 298380.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 298380.KQ
View MoreValuation Measures
Market Cap
1.66T
Enterprise Value
1.57T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
49.76
Price/Book (mrq)
10.11
Enterprise Value/Revenue
46.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-166.24%
Return on Assets (ttm)
-18.93%
Return on Equity (ttm)
-46.01%
Revenue (ttm)
33.4B
Net Income Avi to Common (ttm)
-55.53B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
141.51B
Total Debt/Equity (mrq)
26.10%
Levered Free Cash Flow (ttm)
-62.86B